ABSTRACT
A 79-year-old man with underlying alcoholic liver cirrhosis presented with complaints of a fever, abdominal pain, and difficulty walking. A diagnostic work-up revealed liver atrophy and chylous ascites, and spontaneous bacterial peritonitis (SBP) was diagnosed based on the cell and neutrophil counts. The Burkholderia cepacia complex (Bcc) was detected on blood and ascitic fluid cultures. Although broad-spectrum antibiotic therapy was initiated, the infection was difficult to control, and the patient died of multiple organ failure. Bcc is often multidrug-resistant and difficult to treat. SBP caused by Bcc has been rarely reported and may have a serious course, thus necessitating caution.
Subject(s)
Bacterial Infections , Burkholderia cepacia complex , Peritonitis , Aged , Ascites , Ascitic Fluid , Humans , Liver Cirrhosis/complications , Liver Cirrhosis, Alcoholic , Male , Peritonitis/complications , Peritonitis/diagnosis , Peritonitis/drug therapyABSTRACT
BACKGROUND AND AIMS: Although treatment for hepatitis C virus has been dramatically improved by the development of direct-acting antiviral agents (DAAs), whether interferon (IFN)-free therapy reduces hepatocarcinogenesis in an equivalent manner to IFN-based therapy remains controversial. The aims of this study were to evaluate the occurrence and recurrence of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients treated with DAAs and to identify biomarkers of HCC development after antiviral treatment. METHODS: A restrospective review of a prospective database of 1,897 CHC patients who were treated with IFN-based (1,145) or IFN-free therapies (752) was carried out. Cumulative HCC occurrence and recurrence rates were compared using propensity score-matched analysis. Predictors of HCC development after viral eradication were identified by multivariate analysis. RESULTS: Propensity score-matched analysis showed no significant difference in HCC occurrence (p=0.49) and recurrence rates (p=0.54) between groups treated with IFN-based or IFN-free therapies. In multivariate analysis, higher levels of post-treatment α-fetoprotein (AFP) or Wisteria floribunda agglutinin positive Mac-2 binding protein (WFA+M2BP) were independently associated with HCC occurrence and recurrence after viral eradication. Only post-treatment WFA+M2BP level was significantly associated with HCC occurrence and recurrence among patients without severe fibrosis. The area under the receiver operating characteristic (ROC) curve for WFA+M2BP levels was greater than that for AFP levels in ROC analysis. CONCLUSION: The risks of early HCC occurrence and recurrence after viral eradication were similar between IFN-based and IFN-free therapies. Post-treatment levels of WFA+M2BP may be helpful screening biomarkers for assessing the risk of HCC after IFN-free therapy. Patients with high WFA+M2BP levels after antiviral treatment, even without severe fibrosis, must be followed up carefully for HCC development. Lay summary: The risks of early HCC occurrence and recurrence after viral eradication were similar between IFN-based and IFN-free therapies. Post-treatment levels of WFA+M2BP may be helpful screening biomarkers for assessing the risk of HCC after IFN-free therapy.
Subject(s)
Antiviral Agents/administration & dosage , Carcinoma, Hepatocellular/prevention & control , Hepatitis C, Chronic , Interferons/administration & dosage , Liver Neoplasms/prevention & control , Neoplasm Recurrence, Local , Adult , Aged , Antigens, Neoplasm/analysis , Biomarkers, Tumor/analysis , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/physiopathology , Female , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Humans , Japan/epidemiology , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Liver Neoplasms/physiopathology , Membrane Glycoproteins/analysis , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/etiology , Neoplasm Recurrence, Local/virology , Plant Lectins/analysis , Receptors, N-Acetylglucosamine/analysis , Risk Assessment/methods , Risk Factors , alpha-Fetoproteins/analysisABSTRACT
AIM: Sofosbuvir (SOF) and ribavirin (RBV) combination therapy produces a sustained response in many patients with genotype 2 chronic hepatitis C. However, RBV-induced anemia is a troublesome side-effect that may limit this treatment. Genetic variation leading to inosine triphosphatase (ITPA) deficiency is known to protect against RBV-induced hemolytic anemia. This study aimed to evaluate the relationships between the efficacy and safety of SOF/RBV treatment and ITPA gene variants. METHODS: Ninety patients with genotype 2 chronic hepatitis C treated with SOF/RBV were studied. The relationships among genetic polymorphisms of ITPA and the decline in hemoglobin levels from baseline, RBV dose reduction, and sustained virological response (SVR) rates were analyzed. RESULTS: Overall SVR at 12 weeks was 94.4% (85/90). Patients with the ITPA CA/AA genotypes had a lower degree of anemia throughout the therapy than those with the ITPA CC genotype. The percentage of patients requiring RBV dose reduction was significantly lower for those with the ITPA CA/AA variation, a difference even more apparent when the pretreatment hemoglobin level was <12 g/dL. The dose reduction of RBV and serum albumin level were significantly associated with SVR. CONCLUSIONS: Patients with the ITPA CA/AA genotype were less likely to develop anemia than those with the ITPA CC genotype and were more likely to complete SOF/RBV therapy. These results may provide a valuable pharmacogenetic diagnostic tool to predict drug-induced adverse events, particularly in patients with pre-existing anemia.
ABSTRACT
Fetal hepatic stem/progenitor cells, called hepatoblasts, play central roles in liver organogenesis; however, molecular mechanisms regulating proliferation and terminal differentiation of such cells have not been completely elucidated. Bone morphogenetic protein-4 (BMP-4) is essential for the development of stem cells in various tissues, but its function in regulating the phenotype of hepatoblasts after the mid-gestational fetal stage remains unclear. The aim of this study is to clarify a functional role for BMP-4 in proliferation and terminal differentiation of murine hepatoblasts in mid-gestational fetal livers. METHODS: A functional role for BMP-4 in proliferation and terminal differentiation of murine hepatoblasts was validated by assay of colony formation, biliary luminal formation, and hepatic maturation using primary hepatoblasts in vitro. Molecular mechanisms regulating such effects of BMP-4 on primary hepatoblasts were also analyzed. RESULTS: Stimulation of BMP-4 upregulated phosphorylation of Smad1/5 in hepatoblasts. Bone morphogenetic protein-4 significantly suppressed colony formation of primary hepatoblasts in a dose-dependent manner, significantly suppressed cholangiocytic luminal formation of hepatoblasts, and promoted hepatic maturation of primary hepatoblasts. Stimulation of BMP-4 regulated the activation of several mitogen-activated protein kinases, such as extracellular signal-regulated kinase, Akt, p38 mitogen-activated protein kinase, and calcium/calmodulin-dependent protein kinase IIα in primary hepatoblasts. Moreover, Wnt5a, a molecule regulating cholangiocytic luminal formation, and BMP-4 coordinately suppressed proliferation and cholangiocytic luminal formation of hepatoblasts. CONCLUSION: This study shows that BMP-4-mediated signaling controls proliferation and terminal differentiation of fetal hepatic stem/progenitor cells.
ABSTRACT
Single nucleotide polymorphisms (SNPs) within or near interferon lambda 4 (IFNL4) gene located upstream of IFNL3 are associated with response to anti-HCV therapy both in interferon (IFN)-based and IFN-free regimens. IFNL4 encodes IFNλ4, a newly discovered type III IFN, and its expression is controlled by rs368234815-TT/ΔG, which is in strong linkage disequilibrium (LD) with other tag SNPs within or near IFNL4 such as rs12979860 and rs8099917. Intrahepatic expression levels of IFN-stimulated genes (ISGs) affect the responsiveness to IFNα and are also associated with IFNL4 genotype. However, IFNL4 expressions and its role in intrinsic antiviral innate immunity remain unclear. This study evaluated the effect of IFNL4 on intrahepatic ISG expression and investigated its relationship with treatment outcomes in liver samples obtained from 49 chronic hepatitis C patients treated with pegylated (PEG)-IFN/ribavirin therapy. IFNL4 mRNA was detected in 11 of 22 patients with IFNL4-unfavorable SNPs but not in patients with favorable genotypes. IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy. Intrahepatic expression of antiviral ISGs (ISG15 and MX1) was significantly higher in IFNL4-unfavorable patients with detectable IFNL4 mRNA than in patients with undetectable IFNL4 mRNA, whereas the expression of suppressive ISGs (RNF125, SOCS1, SOCS3, and RNF11) was lower in patients with detectable IFNL4 mRNA. In summary, intrahepatic expression of IFNL4 was associated with increased antiviral ISG expression and decreased suppressive ISG expression at baseline, resulting in poor responsiveness to IFNα-based therapy in HCV infection.
Subject(s)
Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/immunology , Interferons/therapeutic use , Interleukins/genetics , Liver/drug effects , Adult , Aged , Cytokines/genetics , Drug Resistance, Viral , Female , Gene Expression Regulation , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/genetics , Humans , Interferon-alpha/therapeutic use , Interleukins/metabolism , Liver/immunology , Liver/virology , Male , Middle Aged , Myxovirus Resistance Proteins/genetics , Polymorphism, Single Nucleotide , RNA, Messenger , Ribavirin/adverse effects , Ribavirin/therapeutic use , Suppressor of Cytokine Signaling 1 Protein/genetics , Ubiquitins/geneticsABSTRACT
Hepatitis B virus (HBV) is not eradicated by current antiviral therapies due to persistence of HBV covalently closed circular DNA (cccDNA) in host cells, and thus development of novel culture models for productive HBV infection is urgently needed, which will allow the study of HBV cccDNA eradication. To meet this need, we developed culture models of HBV infection using human induced pluripotent stem cell-derived hepatocyte lineages, including immature proliferating hepatic progenitor-like cell lines (iPS-HPCs) and differentiated hepatocyte-like cells (iPS-Heps). These cells were susceptible to HBV infection, produced HBV particles, and maintained innate immune responses. The infection efficiency of HBV in iPS-HPCs predominantly depended on the expression levels of sodium taurocholate cotransporting polypeptide (NTCP), and was low relative to iPS-Heps: however, long-term culture of iPS-Heps was difficult. To provide a model for HBV persistence, iPS-HPCs overexpressing NTCP were established. The long-term persistence of HBV cccDNA was detected in iPS-HPCs overexpressing NTCP, and depended on the inhibition of the Janus-kinase signaling pathway. In conclusion, this study provides evidence that iPS-derived hepatic cell lines can be utilized for novel HBV culture models with genetic variation to investigate the interactions between HBV and host cells and the development of anti-HBV strategies.
Subject(s)
DNA, Circular/genetics , Hepatitis B virus/physiology , Hepatitis B/virology , Hepatocytes/cytology , Induced Pluripotent Stem Cells/cytology , Models, Biological , Organic Anion Transporters, Sodium-Dependent/metabolism , Symporters/metabolism , Cell Differentiation , Cell Line , Cell Proliferation , DNA, Circular/immunology , DNA, Viral/genetics , DNA, Viral/immunology , Hep G2 Cells , Hepatitis B/genetics , Hepatitis B/immunology , Hepatitis B/metabolism , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatocytes/immunology , Hepatocytes/metabolism , Hepatocytes/virology , Humans , Immunity, Innate , Induced Pluripotent Stem Cells/immunology , Induced Pluripotent Stem Cells/metabolism , Induced Pluripotent Stem Cells/virology , MAP Kinase Signaling System , Organic Anion Transporters, Sodium-Dependent/genetics , Symporters/genetics , Transfection , Virus ReplicationABSTRACT
AIM: Wisteria floribunda agglutinin positive (WFA+) Mac-2-binding protein (M2BPGi) is a noninvasive glyco-marker for liver fibrosis. This study evaluated the utility of serial measurement of serum M2BPGi and total M2BP as a predictor of fibrosis and the development of hepatocellular carcinoma (HCC). METHODS: This study included 119 patients with chronic hepatitis C (CHC). Of these patients, 97 were treated with IFN-based therapy and 22 were treated with daclatasvir and asunaprevir. Serum M2BPGi values were measured prior to, at the end of, and at 24 weeks after the completion of treatment. As subanalysis, serum total M2BP levels were measured in patients treated with pegylated-interferon and ribavirin. RESULTS: In patients treated with IFN-based therapy, M2BPGi levels were elevated at the end of treatment but decreased afterwards. In contrast, M2BPGi levels in patients treated with IFN-free therapy decreased immediately after starting the treatment without transient elevation. Though pre-treatment M2BPGi levels significantly correlated with fibrosis in both patients with a sustained virological response (SVR) and non-SVR, post-treatment M2BPGi levels decreased regardless of the degree of fibrosis in patients with SVR. In multivariate analysis, non-SVR and HCC development were independent factors associated with M2BPGi level ≥2.2. In patients treated with pegylated-interferon and ribavirin, total M2BP levels were positively correlated with fibrosis and HCC development. CONCLUSION: Real-time monitoring of the serum M2BPGi level after antiviral therapy for CHC patients could be a helpful screening tool for assessing the risk of HCC. M2BP and its glycan structure could be associated together with hepatocarcinogenesis.
Subject(s)
Antigens, Neoplasm/blood , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/diagnosis , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/diagnosis , Liver Neoplasms/diagnosis , Membrane Glycoproteins/blood , Plant Lectins/blood , Biomarkers, Tumor/blood , Carbamates , Carcinoma, Hepatocellular/metabolism , Carrier Proteins , Early Diagnosis , Female , Glycoproteins , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/metabolism , Humans , Imidazoles/therapeutic use , Interferon-alpha/therapeutic use , Isoquinolines/therapeutic use , Liver Cirrhosis/metabolism , Liver Neoplasms/metabolism , Male , Pyrrolidines , Sulfonamides/therapeutic use , Valine/analogs & derivativesABSTRACT
Fetal hepatic stem/progenitor cells, called hepatoblasts, play central roles in liver development; however, the molecular mechanisms regulating the phenotype of these cells have not been completely elucidated. Matrix metalloproteinase (MMP)-14 is a type I transmembrane proteinase regulating pericellular proteolysis of the extracellular matrix and is essential for the activation of several MMPs and cytokines. However, the physiological functions of MMP-14 in liver development are unknown. Here we describe a functional role for MMP-14 in hepatic and biliary differentiation of mouse hepatoblasts. MMP-14 was upregulated in cells around the portal vein in perinatal stage liver. Formation of bile duct-like structures in MMP-14-deficient livers was significantly delayed compared with wild-type livers in vivo. In vitro biliary differentiation assays showed that formation of cholangiocytic cysts derived from MMP-14-deficient hepatoblasts was completely impaired, and that overexpression of MMP-14 in hepatoblasts promoted the formation of bile duct-like cysts. In contrast, the expression of molecules associated with metabolic functions in hepatocytes, including hepatic nuclear factor 4α and tryptophan 2,3-dioxygenase, were significantly increased in MMP-14-deficient livers. Expression of the epidermal growth factor receptor and phosphorylation of mitogen-activated protein kinases were significantly upregulated in MMP-14-deficient livers. We demonstrate that MMP-14-mediated signaling in fetal hepatic progenitor cells promotes biliary luminal formation around the portal vein and negatively controls the maturation of hepatocytes.
Subject(s)
Bile Ducts/cytology , Bile Ducts/physiology , Liver/cytology , Liver/physiology , Matrix Metalloproteinase 14/metabolism , Stem Cells/enzymology , Animals , Cell Differentiation/physiology , Cell Proliferation/physiology , Cells, Cultured , Mice , Mice, Inbred C57BL , Mice, Knockout , Stem Cells/cytologyABSTRACT
AIM: The presence of resistance-associated variants (RAV) may attenuate the efficacy of direct-acting antivirals (DAA) in combination therapy for hepatitis C. The aim of this study was to characterize the NS3 and NS5A regions of hepatitis C virus (HCV) in naturally occurring RAV. METHODS: The NS3 and NS5A regions of HCV were amplified by nested polymerase chain reaction and their nucleotide sequences were determined by direct sequencing in 493 genotype 1b patients naive to DAA-based therapies. The effect of baseline RAV on response to pegylated interferon and ribavirin therapy was analyzed in 65 patients after stratification by interleukin (IL)-28B genotype. RESULTS: The incidence of RAV was 7.9% in NS3 (V36I/L, 1.2%; T54S, 2.8%; Q80K/R, 3.0%; A156S, 0.2%; and D168E/T, 2.4%) and 20.2% in NS5A (L31I/M, 2.2%; and Y93H, 19.0%). The incidence in interferon experienced and naive patients was similar. The incidence of Y93H in NS5A was significantly higher in the IL-28B TT genotype (rs8099917) than non-TT (27.1% vs 9.5%, P < 0.001). The virological response to pegylated interferon plus ribavirin therapy was not affected by the presence of RAV in IL-28B TT genotype. CONCLUSION: RAV, especially Y93H in the NS5A region, were highly prevalent in DAA naive patients with genotype 1b HCV in Japan and were linked to IL-28B TT genotype. Interferon-based therapy could be an alternative for patients with RAV because these variants did not attenuate the response to that therapy. The analysis of RAV may impact the selection of the optimal treatment strategy.
ABSTRACT
We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the ß-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis. Consecutive patients with cirrhosis and muscle cramps were given L-carnitine 300 mg, 3 times/day (900 mg/day, n = 19) or 4 times/day (1200 mg/day, n = 23) for 8 weeks. The frequency of muscle cramps was assessed by questionnaires, and the degree of muscle cramping was assessed by using the visual analogue scale (VAS). Muscle cramping was reduced in 88.1% of all subjects at the end of the 8-week study period and disappeared for 28.6% of patients. Overall VAS scores decreased significantly from 69.9 ± 22.5 at baseline to 26.2 ± 29.1 after 8 weeks (P < .0001). The dose of L-carnitine was significantly associated with percentages of patients with reduced muscle cramps after 8 weeks (43.5% in the 1200 mg/day group vs 10.5% in the 900 mg/day group, P = .037) and VAS scores at 8 weeks (9.9 ± 13.5 in the 1200 mg/day group vs 39.6 ± 31.9 in the 900 mg/day group, P = .003). No adverse events were reported. Therefore, L-carnitine appears to be safe and effective for reducing liver cramps in patients with cirrhosis.
Subject(s)
Carnitine/administration & dosage , Liver Cirrhosis/complications , Muscle Cramp/drug therapy , Muscle Cramp/pathology , Carnitine/adverse effects , Drug-Related Side Effects and Adverse Reactions/epidemiology , Humans , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires , Treatment OutcomeABSTRACT
A novel N-acyl-D-amino acid amidohydrolase (DAA) was purified from the cells of a novel species of the genus Microbacterium. The purified enzyme, termed AcyM, was a monomeric protein with an apparent molecular weight of 56,000. It acted on N-acylated hydrophobic D-amino acids with the highest preference for N-acetyl-D-phenylalanine (NADF). Optimum temperature and pH for the hydrolysis of NADF were 45°C and pH 8.5, respectively. The k(cat) and K(m) values for NADF were 41 s⻹ and 2.5 mM at 37°C and pH 8.0, although the enzyme activity was inhibited by high concentrations of NADF. Although many known DAAs are inhibited by 1 mM EDTA, AcyM displayed a 65% level of its full activity even in the presence of 20 mM EDTA. Based on partial amino acid sequences of the purified enzyme, the full-length AcyM gene was cloned and sequenced. It encoded a protein of 495 amino acids with a relatively low sequence similarity to a DAA from Alcaligenes faecalis DA1 (termed AFD), a binuclear zinc enzyme of the α/ß-barrel amidohydrolase superfamily. The unique cysteine residue that serves as a ligand to the active-site zinc ions in AFD and other DAAs was not conserved in AcyM and was replaced by alanine. AcyM was the most closely related to a DAA of Gluconobacter oxydans (termed Gox1177) and phylogenetically distant from AFD and all other DAAs that have been biochemically characterized thus far. AcyM, along with Gox1177, appears to represent a new phylogenetic subcluster of DAAs.
Subject(s)
Actinomycetales/enzymology , Amidohydrolases/chemistry , Amidohydrolases/isolation & purification , Amino Acids/biosynthesis , Industrial Microbiology , Amidohydrolases/genetics , Amidohydrolases/metabolism , Amino Acid Sequence , Amino Acids/chemistry , Amino Acids/genetics , Amino Acids/isolation & purification , Cloning, Molecular , Molecular Sequence Data , Molecular Weight , Phylogeny , Sequence Alignment , TemperatureABSTRACT
OBJECTIVE: The purpose of this research is to clarify the effects of the following treatments on the elution of trace elements: water settling, 2 h boiling of water, acetic acid settling, and 2 h boiling of acetic acid in prebrushed enameled cookware, and the same four treatments after brushing the surface of enameled cookware. METHOD: The eluate samples from enameled cookware subjected to the above eight treatments ware obtained, and the concentrations of the fifteen trace elements (B, Al, Cr, Mn, Fe, Ni, Cu, Zn, As, Se, Mo, Cd, Sb, Pb, and U) were simultaneously analyzed by inductively coupled plasma-mass spectrometry (ICP-MS). RESULTS: The concentrations of the fifteen elements eluted from enameled cookware were low or very low after the treatments. Enameled cookware is made from iron covered with glass containing pigments. The concentrations of Al, Ni, and Sb were significantly higher (p<0.01) in almost all treatments. The concentrations of Fe, which is the base element of enameled cookware, showed almost no change. The safety level for enameled cookware are standardized at 70 ng/mL Cd and 400 ng/mL Pb. The Cd and Pb concentrations in all treatment samples were below these standard levels. CONCLUSION: The results of our study and other studies conducted so far suggest that the risk of acute or chronic toxicity associated with the use of enameled cookware under normal circumstances is extremely low and negligible.
Subject(s)
Cooking and Eating Utensils , Trace Elements/analysis , Tandem Mass Spectrometry/methodsABSTRACT
A rod-shaped, Gram-positive bacterium, strain TNJL143-2(T), having N-acyl-D-amino acid amidohydrolase (D-aminoacylase) activity, was isolated from a soil sample from Natori, Japan. It was a non-spore-forming, strictly aerobic bacterium without motility, showing a temperature optimum for growth of 30 degrees C and a pH optimum for growth of 5-7. The 16S rRNA gene sequence of the strain showed the highest similarities to members of the genus Microbacterium, in particular, Microbacterium aerolatum, Microbacterium foliorum and Microbacterium phyllosphaerae. The chemotaxonomic characteristics, including the compositions of cellular menaquinones, cellular fatty acids and cell-wall amino acids, were consistent with those described for the genus Microbacterium. The G+C content of the genomic DNA was determined as 69.1 mol%. DNA-DNA hybridization studies using type strains of M. aerolatum, M. foliorum and M. phyllosphaerae showed only low levels of relatedness (11-12 %). On the basis of these phenotypic and genotypic results, a novel species, Microbacterium natoriense sp. nov., is proposed, with TNJL143-2(T) (=JCM 12611(T)=ATCC BAA-1032(T)) as the type strain.